Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
Head-To-Head Review: Medical Transcription Billing, Corp. (MTBC) versus Fluidigm Corporation (FLDM)
Medical Transcription Billing, Corp. (NASDAQ: MTBC) and Fluidigm Corporation (NASDAQ:FLDM) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitabiliy, risk, valuation, earnings and analyst recommendations.
Receive News & Ratings for Medical Transcription Billing Corp. Daily
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
Insider and Institutional Ownership
9.6% of Medical Transcription Billing, Corp. shares are owned by institutional investors. Comparatively, 91.7% of Fluidigm Corporation shares are owned by institutional investors. 53.5% of Medical Transcription Billing, Corp. shares are owned by company insiders. Comparatively, 4.7% of Fluidigm Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Medical Transcription Billing, Corp. and Fluidigm Corporation, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medical Transcription Billing, Corp. | 0 | 0 | 1 | 0 | 3.00 |
| Fluidigm Corporation | 0 | 0 | 1 | 0 | 3.00 |
Medical Transcription Billing, Corp. currently has a consensus price target of $2.25, indicating a potential upside of 55.16%. Fluidigm Corporation has a consensus price target of $9.00, indicating a potential upside of 191.26%. Given Fluidigm Corporation’s higher possible upside, analysts clearly believe Fluidigm Corporation is more favorable than Medical Transcription Billing, Corp..
Profitability
This table compares Medical Transcription Billing, Corp. and Fluidigm Corporation’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medical Transcription Billing, Corp. | -32.88% | -59.52% | -19.17% |
| Fluidigm Corporation | -74.05% | -104.38% | -18.13% |
Earnings & Valuation
This table compares Medical Transcription Billing, Corp. and Fluidigm Corporation’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Medical Transcription Billing, Corp. | $27.60 million | 0.53 | -$3.02 million | ($1.08) | -1.34 |
| Fluidigm Corporation | $100.98 million | 0.90 | -$64.73 million | ($2.46) | -1.26 |
Medical Transcription Billing, Corp. has higher revenue, but lower earnings than Fluidigm Corporation. Medical Transcription Billing, Corp. is trading at a lower price-to-earnings ratio than Fluidigm Corporation, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Medical Transcription Billing, Corp. has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Fluidigm Corporation has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.
Summary
Fluidigm Corporation beats Medical Transcription Billing, Corp. on 6 of the 11 factors compared between the two stocks.
About Medical Transcription Billing, Corp.
About Fluidigm Corporation